Risk factors associated with comorbid asthma in patients with chronic rhinosinusitis with nasal polyps: a cross-sectional study

Table 3 Baseline and clinical characteristics of patients with CRSwNP enrolled for validation of screening system

Parameter	Whole group (n = 78)	CRSwNP with asthma (n = 39)	CRSwNP without asthma (n = 39)	P value
Female, n (%)	32 (41.0)	23 (59.0)	9 (31.1)	0.001*
Age, years	48.2 ± 12.1	48.1 ± 13.0	48.3 ± 11.4	0.941
BMI, kg/m²	24.8 ± 3.1	24.0 ± 3.0	25.6 ± 3.0	0.027*
Smokers, n (%)	13 (16.7)	4 (10.3)	9(23.1)	0.129
Pack-years smoked	11.3 (10.0, 28.1)	16.3 (10.6, 21.9)	10.0 (4.8, 30.0)	0.665
History of allergic rhinitis, n (%)	20 (25.6)	13 (33.3)	7 (17.9)	0.120
Nasal obstruction duration, years	2.0 (1.0, 8.0)	3.0 (1.0, 8.0)	2.0 (1.0, 10.0)	0.984
Blood eosinophil percentage, %	5.8 ± 3.6	7.4 ± 3.9	4.2 ± 2.4	< 0.001*
Blood eosinophil count, × 10⁹/L	0.4 ± 0.2	0.5 ± 0.3	0.3 ± 0.1	< 0.001*
Serum T-IgE, kU/L	113.0 (49.8, 264.5)	191.0 (100.0, 367.0)	64.2 (34.0, 172.0)	< 0.001*

Data are presented as No. (%) for qualitative variables, as mean ± standard deviation for normal distribution quantitative parameters, as median (25th, 75th percentiles) for abnormal distribution quantitative parameters
CRSwNP Chronic rhinosinusitis with nasal polyps; BMI Body mass index; T-IgE Total immunoglobulin E
* Statistical significance between CRSwNP with asthma and CRSwNP without asthma

ISSN: 1471-2466